Ben Clevenger's questions to Globus Medical Inc (GMED) leadership • Q4 2024
Question
Ben Clevenger, on for Richard Newitter at Truist Securities, asked about the key considerations that could drive results to the high or low end of the 2025 EPS guidance range that includes the Nevro acquisition. He also inquired about potential tariff exposure.
Answer
CFO Keith Pfeil explained that the EPS range for the combined company will be influenced by sales performance and the ability to control the cost structure of the acquired Nevro business. Regarding tariffs, Pfeil and CEO Dan Scavilla stated that exposure is 'extremely immaterial,' as approximately 95% of products are U.S.-based or sourced, with the remainder being mostly long-term instrumentation.